Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37827878

about

Modulation of Autophagy by Sorafenib: Effects on Treatment Response Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.Hepatoid Adenocarcinoma of the Gallbladder : Case Report and Literature Review.Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.

P2860

Q26745320-A59F6258-9DCA-47A4-A149-E883E4B59863 Q35984385-54DD6F9E-B6F5-488D-BB89-D7836BC71F34 Q36223025-5F8BF0DA-793B-465E-B073-BC232125E636 Q36962089-EF19CA5D-8A7E-4781-BE9C-4B7A1070B5C3 Q37936344-2403457F-2B38-4DF9-B611-3FB8C45254A3 Q38022245-01A5DF71-0486-4781-8667-D468E1172C5C Q38635474-ED844194-5D6E-49E7-A595-855AEB4C7095 Q38725944-A981DFC6-BEA9-49C7-AB31-6B7EDF1BC163 Q39270291-D363C8B9-2EA5-4671-BB8B-F128FFBFC7FB Q42173132-B920D98F-CD64-4629-8C08-AD0AB5BB6F88 Q51007060-CD1B1B2F-638C-474C-93A2-41FE7270E314 Q54489566-074F0BF3-0E4E-4A88-A76F-F6643E670E41

P2860

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37827878

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@en

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@nl

type

label

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@en

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@nl

prefLabel

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@en

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@nl

P1433

Q37827878-919B829A-6727-4EEB-9121-5CACAD534D47

P1476

Q37827878-DED67D7A-A077-4A6A-81C0-68033FE7B21F

P2093

Q37827878-35BA944E-149C-4F0C-B4DE-EAA4C05C7E09

Q37827878-A1C2A44F-631C-42DE-856A-9607E5F6E0F1

P2860

Q37827878-013C84BE-F9F2-4C5F-B95A-A0F7219E3380

Q37827878-13BBCBCB-BAB2-4722-83C6-C4E47F642A9C

Q37827878-15B136CF-1519-4B71-9129-D6A7A755B13C

Q37827878-1BC3130D-F3A0-4C42-8937-9B136F8177E8

Q37827878-1E12B6BD-7E45-4CB9-BE71-B13D61AA7D4C

Q37827878-1EB8E696-210D-4F59-98BC-E8B1B8741C7D

Q37827878-21B52CC3-42A8-4DA4-9767-0A45F9530E1E

Q37827878-22B1A710-4D34-4794-9795-293528C86057

Q37827878-248CA901-60AE-45D5-AAF9-B6FB27770CA1

Q37827878-2C7C51A1-1460-4146-9B7B-EBFC965C54DB

P304

Q37827878-F4E71425-A50D-487C-9C4D-F6777F43E1B8

P31

Q37827878-E2A69B84-D075-4A24-A61B-CC126EB9EAB2

P356

Q37827878-62B7FADC-F5B4-41AA-90BE-79B836A03D09

P407

Q37827878-A825237A-B6CF-4CBD-9BB4-DC4B3294F5B0

P433

Q37827878-946D0239-7CE4-4D54-8F2C-6EA3FC6F1C5E

P478

Q37827878-AF6FE515-6F8D-4B0E-A9C9-707763A1EA44

P577

Q37827878-992A813A-FCD7-4283-BE4C-B945A59056CA

P698

Q37827878-5AB8D406-B947-4A4B-99DA-C406EE2AE10F

P356

14656566.2011.546346

P1433

Expert Opinion on Pharmacotherapy

P1476

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

@en

P2093

Qing He

http://www.w3.org/2001/XMLSchema#string

Yong-Song Guan

http://www.w3.org/2001/XMLSchema#string

P2860

ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF

Sorafenib in advanced hepatocellular carcinoma

Sorafenib: a review of its use in advanced hepatocellular carcinoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a pha

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.

P304

303-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.546346

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21226640

http://www.w3.org/2001/XMLSchema#string